|
Code
|
Display
|
|
54
|
adenovirus, type 4 |
|
55
|
adenovirus, type 7 |
|
82
|
adenovirus, unspecified formulation |
|
24
|
anthrax |
|
19
|
BCG |
|
27
|
botulinum antitoxin |
|
26
|
cholera, unspecified formulation |
|
29
|
CMVIG |
|
56
|
dengue fever tetravalent |
|
12
|
diphtheria antitoxin |
|
28
|
DT (pediatric) |
|
20
|
DTaP |
|
106
|
DTaP, 5 pertussis antigens |
|
107
|
DTaP, unspecified formulation |
|
110
|
DTaP-Hep B-IPV |
|
50
|
DTaP-Hib |
|
120
|
DTaP-Hib-IPV |
|
130
|
DTaP-IPV |
|
1
|
DTP |
|
22
|
DTP-Hib |
|
102
|
DTP-Hib-Hep B |
|
57
|
hantavirus |
|
52
|
Hep A, adult |
|
83
|
Hep A, ped/adol, 2 dose |
|
84
|
Hep A, ped/adol, 3 dose |
|
31
|
Hep A, pediatric, unspecified formulation |
|
85
|
Hep A, unspecified formulation |
|
104
|
Hep A-Hep B |
|
30
|
HBIG |
|
8
|
Hep B, adolescent or pediatric |
|
42
|
Hep B, adolescent/high risk infant |
|
43
|
Hep B, adult |
|
44
|
Hep B, dialysis |
|
45
|
Hep B, unspecified formulation |
|
58
|
Hep C |
|
59
|
Hep E |
|
60
|
herpes simplex 2 |
|
46
|
Hib (PRP-D) |
|
47
|
Hib (HbOC) |
|
48
|
Hib (PRP-T) |
|
49
|
Hib (PRP-OMP) |
|
17
|
Hib, unspecified formulation |
|
51
|
Hib-Hep B |
|
61
|
HIV |
|
118
|
HPV, bivalent |
|
62
|
HPV, quadrivalent |
|
86
|
IG |
|
87
|
IGIV |
|
14
|
IG, unspecified formulation |
|
111
|
influenza, live, intranasal |
|
15
|
influenza, split (incl. purified surface antigen) |
|
16
|
influenza, whole |
|
88
|
influenza, unspecified formulation |
|
123
|
influenza, H5N1-1203 |
|
10
|
IPV |
|
2
|
OPV |
|
89
|
polio, unspecified formulation |
|
39
|
Japanese encephalitis SC |
|
63
|
Junin virus |
|
64
|
leishmaniasis |
|
65
|
leprosy |
|
66
|
Lyme disease |
|
3
|
MMR |
|
4
|
M/R |
|
94
|
MMRV |
|
67
|
malaria |
|
5
|
measles |
|
68
|
melanoma |
|
32
|
meningococcal MPSV4 |
|
103
|
meningococcal C conjugate |
|
114
|
meningococcal MCV4P |
|
108
|
meningococcal ACWY, unspecified formulation |
|
7
|
mumps |
|
69
|
parainfluenza-3 |
|
11
|
pertussis |
|
23
|
plague |
|
33
|
pneumococcal polysaccharide PPV23 |
|
100
|
pneumococcal conjugate PCV 7 |
|
109
|
pneumococcal, unspecified formulation |
|
70
|
Q fever |
|
18
|
rabies, intramuscular injection |
|
40
|
rabies, intradermal injection |
|
90
|
rabies, unspecified formulation |
|
72
|
rheumatic fever |
|
73
|
Rift Valley fever |
|
34
|
RIG |
|
119
|
rotavirus, monovalent |
|
122
|
rotavirus, unspecified formulation |
|
116
|
rotavirus, pentavalent |
|
74
|
rotavirus, tetravalent |
|
71
|
RSV-IGIV |
|
93
|
RSV-MAb |
|
6
|
rubella |
|
38
|
rubella/mumps |
|
76
|
Staphylococcus bacterio lysate |
|
113
|
Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed |
|
9
|
Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed |
|
115
|
Tdap |
|
35
|
tetanus toxoid, adsorbed |
|
112
|
tetanus toxoid, unspecified formulation |
|
77
|
Tick-borne encephalitis vaccine (non-US) |
|
13
|
TIG |
|
95
|
TST-OT tine test |
|
96
|
TST-PPD intradermal |
|
97
|
TST-PPD tine test |
|
98
|
TST, unspecified formulation |
|
78
|
tularemia vaccine |
|
91
|
typhoid, unspecified formulation |
|
25
|
typhoid, oral |
|
41
|
typhoid, parenteral |
|
53
|
typhoid, parenteral, AKD (U.S. military) |
|
101
|
typhoid, ViCPs |
|
75
|
vaccinia (smallpox) |
|
105
|
vaccinia (smallpox) diluted |
|
79
|
vaccinia immune globulin |
|
21
|
varicella |
|
81
|
VEE, inactivated |
|
80
|
VEE, live |
|
92
|
VEE, unspecified formulation |
|
36
|
VZIG |
|
117
|
VZIG (IND) |
|
37
|
yellow fever |
|
121
|
zoster live |
|
998
|
no vaccine administered |
|
999
|
unknown |
|
99
|
RESERVED - do not use |
|
133
|
Pneumococcal conjugate PCV 13 |
|
134
|
Japanese Encephalitis IM |
|
137
|
HPV, unspecified formulation |
|
136
|
Meningococcal MCV4O |
|
135
|
Influenza, high dose seasonal |
|
131
|
typhus, historical |
|
132
|
DTaP-IPV-HIB-HEP B, historical |
|
128
|
Novel Influenza-H1N1-09, all formulations |
|
125
|
Novel Influenza-H1N1-09, nasal |
|
126
|
Novel influenza-H1N1-09, preservative-free |
|
127
|
Novel influenza-H1N1-09 |
|
138
|
Td (adult) |
|
139
|
Td(adult) unspecified formulation |
|
140
|
Influenza, seasonal, injectable, preservative free |
|
129
|
Japanese Encephalitis, unspecified formulation |
|
141
|
Influenza, seasonal, injectable |
|
142
|
tetanus toxoid, not adsorbed |
|
143
|
Adenovirus types 4 and 7 |
|
144
|
influenza, seasonal, intradermal, preservative free |
|
145
|
RSV-MAb (new) |
|
146
|
DTaP,IPV,Hib,HepB |
|
147
|
meningococcal MCV4, unspecified formulation |
|
148
|
Meningococcal C/Y-HIB PRP |
|
149
|
influenza, live, intranasal, quadrivalent |
|
150
|
influenza, injectable, quadrivalent, preservative free |
|
151
|
influenza nasal, unspecified formulation |
|
152
|
Pneumococcal Conjugate, unspecified formulation |
|
153
|
Influenza, injectable, MDCK, preservative free |
|
154
|
Hep A, IG |
|
155
|
influenza, recombinant, injectable, preservative free |
|
156
|
Rho(D)-IG |
|
157
|
Rho(D) -IG IM |
|
158
|
influenza, injectable, quadrivalent |
|
159
|
Rho(D) - Unspecified formulation |
|
160
|
Influenza A monovalent (H5N1), ADJUVANTED-2013 |
|
801
|
AS03 Adjuvant |
|
161
|
Influenza, injectable,quadrivalent, preservative free, pediatric |
|
162
|
meningococcal B, recombinant |
|
163
|
meningococcal B, OMV |
|
164
|
meningococcal B, unspecified |
|
165
|
HPV9 |
|
166
|
influenza, intradermal, quadrivalent, preservative free |
|
167
|
meningococcal, unknown serogroups |
|
168
|
influenza, trivalent, adjuvanted |
|
169
|
Hep A, live attenuated |
|
170
|
DTAP/IPV/HIB - non-US |
|
171
|
Influenza, injectable, MDCK, preservative free, quadrivalent |
|
172
|
cholera, WC-rBS |
|
173
|
cholera, BivWC |
|
174
|
cholera, live attenuated |
|
175
|
Rabies - IM Diploid cell culture |
|
176
|
Rabies - IM fibroblast culture |
|
177
|
PCV10 |
|
178
|
OPV bivalent |
|
179
|
OPV ,monovalent, unspecified |
|
180
|
tetanus immune globulin |
|
181
|
anthrax immune globulin |
|
182
|
OPV, Unspecified |
|
183
|
Yellow fever vaccine - alt |
|
184
|
Yellow fever, unspecified formulation |
|
185
|
influenza, recombinant, quadrivalent,injectable, preservative free |
|
186
|
Influenza, injectable, MDCK, quadrivalent, preservative |
|
187
|
zoster recombinant |
|
188
|
zoster, unspecified formulation |
|
189
|
HepB-CpG |
|
190
|
Typhoid conjugate vaccine (TCV) |
|
191
|
meningococcal A polysaccharide (non-US) |
|
192
|
meningococcal AC polysaccharide (non-US) |
|
193
|
Hep A-Hep B, pediatric/adolescent |
|
194
|
Influenza, Southern Hemisphere |
|
195
|
DT, IPV adsorbed |
|
196
|
Td, adsorbed, preservative free, adult use, Lf unspecified |
|
197
|
influenza, high-dose, quadrivalent |
|
200
|
influenza, Southern Hemisphere, pediatric, preservative free |
|
201
|
influenza, Southern Hemisphere, preservative free |
|
202
|
influenza, Southern Hemisphere, quadrivalent, with preservative |
|
198
|
DTP-hepB-Hib Pentavalent Non-US |
|
203
|
meningococcal conjugate quadrivalent, MenACWY-TT (MCV4) |
|
205
|
Influenza vaccine, quadrivalent, adjuvanted |
|
206
|
Vaccinia, smallpox Mpox vaccine live, PF, SQ or ID injection |
|
207
|
COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose |
|
208
|
COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose |
|
213
|
SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED |
|
210
|
COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL |
|
212
|
COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL |
|
204
|
Ebola Zaire vaccine, live, recombinant, 1mL dose |
|
214
|
Ebola, unspecified |
|
211
|
COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL |
|
500
|
COVID-19 Non-US Vaccine, Product Unknown |
|
501
|
COVID-19 IV Non-US Vaccine (QAZCOVID-IN) |
|
502
|
COVID-19 IV Non-US Vaccine (COVAXIN) |
|
503
|
COVID-19 LAV Non-US Vaccine (COVIVAC) |
|
504
|
COVID-19 VVnr Non-US Vaccine (Sputnik Light) |
|
505
|
COVID-19 VVnr Non-US Vaccine (Sputnik V) |
|
506
|
COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology |
|
507
|
COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharm + Inst of Micro, Chinese Acad of Sciences) |
|
508
|
COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention) |
|
509
|
COVID-19 PS Non-US Vaccine (EpiVacCorona) |
|
510
|
COVID-19 IV Non-US Vaccine (BIBP, Sinopharm) |
|
511
|
COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac) |
|
215
|
Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF |
|
216
|
Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF |
|
219
|
COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose |
|
217
|
COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose |
|
218
|
COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose |
|
220
|
HepB recombinant, 3-antigen, Al(OH)3 |
|
221
|
COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose |
|
222
|
Tick-borne encephalitis, unspecified |
|
223
|
Tick-borne encephalitis, inactivated, PF, 0.25mL |
|
224
|
Tick-borne encephalitis, inactivated, PF, 0.5mL |
|
225
|
COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL |
|
226
|
COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 10mcg/0.5mL |
|
512
|
SARS-COV-2 COVID-19 VLP Non-US Vaccine (Medicago, Covifenz) |
|
513
|
SARS-COV-2 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax) |
|
514
|
SARS-COV-2 COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D) |
|
515
|
SARS-COV-2 COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901) |
|
516
|
COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC) |
|
517
|
SARS-COV-2 COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax) |
|
227
|
COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose |
|
228
|
COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose |
|
229
|
COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose |
|
301
|
COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose |
|
300
|
COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose |
|
230
|
COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL |
|
518
|
COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva) |
|
519
|
COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna |
|
520
|
COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech |
|
521
|
COVID-19 SP, protein-based, adjuvanted (VidPrevtyn Beta), Sanofi-GSK |
|
231
|
influenza, Southern Hemisphere, high-dose, quadrivalent |
|
303
|
RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF |
|
304
|
Respiratory syncytial virus (RSV), unspecified |
|
302
|
COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose |